Polymyxin antibiotics for gram-negative infections (Q36786226)

16 August 2017

1 reference

title

Polymyxin antibiotics for gram-negative infections (English)

1 reference

16 August 2017

main subject

gram-negative bacteria

0 references

0 references

Tamra M Arnold

1 reference

16 August 2017

Graeme N Forrest

series ordinal

1 reference

16 August 2017

Karen J Messmer

series ordinal

1 reference

16 August 2017

publication date

1 April 2007

1 reference

American Journal of Health-System Pharmacy

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

819-826

1 reference

Infection control in the ICU.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Nosocomial bacterial infections in Intensive Care Units. I: Organisms and mechanisms of antibiotic resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

The impact of antimicrobial resistance on health and economic outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Aerosol Polymyxin and Pneumonia in Seriously Ill Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

The Mode of Action of Antibiotics on Gram-Negative Bacilli

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

A reassessment of the in-vitro activity of colistin sulphomethate sodium

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Antibiotic susceptibility of gram-negative bacilli isolated from blood cultures. Results of tests with 35 agents and strains from 169 patients at Boston City Hospital during 1972.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Tetracycline, chloramphenicol, kanamycin, and colistimethate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Use of intravenous polymyxin B during continuous venovenous hemodialysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Colistimethate toxicity. Report of a fatal case in a previously healthy child

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

"Colomycin". Laboratory and clinical investigations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

POLYMYXIN B AND COLISTIN. A CRITICAL COMPARISON

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Effects of Large Doses of Colistin Sulphomethate Sodium on Renal Function

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Recovery from Colistimethate Nephrotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

SODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINS

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Studies on the Compounds related to Colistin. IX. On the Chemical Deacylation of Colistin and Colistin Derivatives

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumannii

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Colistin: an antimicrobial for the 21st century?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Use of colistin in the treatment of multiple-drug-resistant gram-negative infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060473

31 March 2020

Identifiers

DOI

10.2146/AJHP060473

1 reference

16 August 2017

1 reference